期刊
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
卷 268, 期 5, 页码 519-524出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00406-017-0815-9
关键词
Soluble amyloid precursor protein beta (sAPP beta); Biomarker-underpinned diagnoses; FDG-PET; Upstream biomarkers; Mild cognitive impairment; Dementia due to Alzheimer's disease
The established biomarkers of Alzheimer's disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein beta (sAPP beta), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPP beta in plasma as an AD biomarker candidate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据